Drug Profile
Research programme: seasonal influenza vaccines - AmVac
Alternative Names: AMV 401; FluVac - AmVac; Influenza vaccine - AmVac/Bayer Innovation GmbH; Universal influenza vaccine - AmVacLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator AmVac
- Class Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza virus infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Influenza-virus-infections(Prevention) in Switzerland (Intranasal)
- 02 Dec 2014 Preclinical development is ongoing in Switzerland
- 20 Jun 2013 AmVac receives an EU grant of €6 million to support development of its universal influenza vaccine